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Introduction and Objective
Varicella (also known as chickenpox) is an acute and highly contagious 
disease caused by the varicella-zoster virus (VZV) and is a common 
childhood disease. The epidemiology of varicella has changed dramatically 
since introduction of the varicella vaccines that are highly effective in 
reducing the global incidence and burden of the disease. In the Republic of 
Korea, however, incidence of varicella has been increasing during 2006 to 
2017 despite the implementation of a routine one-dose varicella vaccination 
program in 2005. This study was to investigate the changes in the 
epidemiology of varicella following the introduction of vaccination and to 
evaluate the vaccine effectiveness in Korea. The objectives are as follows: 
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   (1) identify the effect of age, period, and birth cohort on increasing 
temporal trend of varicella incidence among children in Korea by 
conducting Age-Period-Cohort(APC) analysis. 
   (2) identify spatial patterns in varicella incidence and geographical risk 
factors of the disease by spatial analysis and fitting spatial regression 
model. 
   (3) evaluate the effectiveness of universal one-dose vaccination program 
on the incidence of varicella by performing a matched case-control 
study. 
   (4) assess the effect of varicella vaccination on disease severity despite 
that the vaccination might fail to protect against varicella incidence.
Methods
   (1) Varicella incidence from January 2006 to December 2017 was 
obtained from the National Notifiable Disease Surveillance System 
data. Population statistics were available from the Korean National 
Statistics Office. The APC model was used to estimate the age, 
period, and cohort effects. APC analysis was conducted by the APC 
Web Tool proposed by Rosenberg.
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   (2) Varicella incidence of 250 districts (si-gun-gu) from January 2006 to 
December 2017 was also obtained from the National Notifiable 
Disease Surveillance System data. Sociodemographic data were 
available from the Korean National Statistics Office. Global (Moran’s I)
and local (LISA) spatial autocorrelation were calculated. Spatial 
regression analysis was performed to find sociodemographic 
predictors of varicella incidence to district level using spatial lag and 
spatial error model.
   (3) The 537 cases and their individually matched controls were collected 
from the National Notifiable Disease Surveillance System. All 
confirmed cases were children with varicella in Seoul, Korea, 
between January 2013 and December 2013. To estimate the 
effectiveness of one-dose vaccination, conditional logistic regression 
analysis on the 1:1 matched pairs was performed after adjusting for 
the effects of possible confounders such as sex and age at 
vaccination. When calculating the effect of time since vaccination, 
we used conditional logistic models with dummy-coded variables. 
   (4) A total of 1,125 varicella cases reported as part of epidemiologic 
investigation of varicella from January 2015 to December 2017 in 
Seoul Metropolitan City were used. Data was provided by Korea 
Centers for Disease Control and Prevention (KCDC). Disease severity 
of patients was assessed by the number of skin lesions. Binary 
unconditional logistic regression analysis was performed to examine 
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the differences in disease severity between the two groups with 
factor of age controlled. 
Results
   (1) Varicella incidence and age-standardized incidence rates have shown 
a diagonally upward trend between 2006 and 2017. During the 
period, the incidence rate also increased for each age strata among 
children aged 0 to 12–year–old with age peak shifted from 4 to 6 
years old. In the APC analysis, period and cohort curves showed 
similar increasing patterns. 
   (2) Local spatial clusters with high level of varicella incidence were 
initially confined to northeast region (Gangwon-do), rural and 
mountain area. In later, the ‘hot spots’ gradually spread to their 
neighboring districts and faded out over time, which led overall 
increase in incidence across the country. In spatial regression 
analysis, childhood percentage was risk factors on the incidence of 
varicella at district level while factors such as population density and 
number of hospitals have negative effect on the risk. Meanwhile,
vaccine coverage rate was an insignificant factor on the incidence of 
varicella.
   (3) In a matched case-control study, the overall effectiveness of one-dose 
varicella vaccination in preventing confirmed cases of varicella was 
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low (13%, 95% CI: -17.3–35.6) and the vaccine effectiveness sharply 
declined after the three year of vaccination due to waning of 
immunity. In specific, The fact that more than half of all vaccinees 
were immunized with the vaccine based on MAV strain, which only 
available in Korea, was distinct from the cases in other countries.
   (4) Among a total of 1,008 varicella cases in Seoul, Korea, 869 cases 
(86.2%) were breakthrough cases and 139 (13.8%) were unvaccinated 
cases. The risk for severe illness was significantly decreased in 
breakthrough group than unvaccinated group. The risk for occurrence 
of moderate-to-severe disease in the breakthrough group was less 
than roughly half that of the unvaccinated group (OR = 0.570, CI: 
0.365–0.890). 
Conclusions
   (1) The study describes the post-licensure epidemiology of varicella 
incidence with an aspect of time and age. The increasing trend in 
varicella incidence may be explained by  vaccine failure. The age 
peak shifting could be associated with secondary failure, which 
relates to the waning of vaccine-induced immunity over time. The 
varicella vaccine is merely effective in the early years, but, in later, 
the incidence of breakthrough infection jumps as immunity rapidly 
wanes over time.
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   (2) The second study describes the post-licensure epidemiology of 
varicella incidence with an aspect of time and space. The result 
indicated that where have a low population density and a few 
healthcare providers and a high childhood percentage were 
vulnerable to varicella outbreak, while vaccine coverage showed no 
influence on the incidence due to its high vaccination rate. The 
overall increase in varicella incidence in Korea could be attributed 
by spread out of varicella from high incidence cluster to its
neighboring districts.
   (3) The third study was to evaluate the effectiveness of one-dose 
varicella vaccination program in Korea. A low effectiveness of 
vaccine and a rapid waning of immunity of administered vaccine in 
Korea suggested there is primary or/and secondary vaccine failure. 
This finding may provide a key to understand the increasing trend of
varicella incidence following implementation of universal vaccination 
program in Korea. Due to an insufficient immunogenicity of the 
vaccine might have limited effectiveness to decrease in the incidence 
of varicella. 
   (4) The last study also assessed vaccine effectiveness with an aspect of 
effects on disease severity. The result suggested that one-dose 
vaccination was associated with the attenuation of disease severity in 
children varicella cases. Patients whose mild symptoms can also 
transmit varicella to others and often cause failure to isolation, 
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leading to outbreaks among those with close contacts in education 
facilities. Therefore, a recent increase in the incidence rate of 
varicella in Korea may be associated with a growing number of 
breakthrough cases 
Key words : varicella, chicken pox, Age-period-cohort, case-control study, 
Spatial lag regression, Republic of Korea
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1-1. Epidemiology of varicella and vaccine introduction
     Varicella (also known as chickenpox) is an acute and highly 
contagious disease caused by the varicella-zoster virus (VZV) and is a 
common childhood disease. VZV is highly transmissible via respiratory 
droplets or direct contact with characteristic skin lesions of the infected 
person. Varicella is generally a mild disease, but severe complications may 
occur more often in adults, including infections of the lung (pneumonia) and 
neurological complications (e.g. encephalitis). Following primary infection, 
herpes zoster (also called shingles) may arise by reactivation of the same 
virus that remains latent in nerve cells. This usually occurs in adults aged 
50 years or older and is accompanied by a painful rash.
     The epidemiology of varicella has changed dramatically since 
introduction of the varicella vaccines that are highly effective in reducing 
the global incidence and burden of the disease [1]. The live attenuated 
vaccine was first developed based on the Oka VZV strain in 1974 and is 
now used widely in many countries. Although not universally adopted, 
WHO recommends that varicella vaccination should be introduced into 
routine immunization program. In December 2014, varicella vaccines were 
recommended 33 predominantly higher socioeconomic status countries [2].   
     The United States was the first country that adopted a universal 
varicella vaccination. In the US, routine one–dose vaccination of all children 
between the ages of 12 and 18 months was implemented in 1996 and has 
resulted in decreases in the incidence from 1.1–3.8 cases per 1,000 
population between 1990 and 1994 to 0.3–1.0 cases between 1999 and 2001 
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[3]. The vaccine effectiveness of one-dose vaccination was estimated to be 
85% (95% CI: 78–90%; p < 0.001) [4]. In Germany, where a routine 
varicella vaccination program was introduced in 2004, vaccination coverage 
between 2006 and 2011 was only 38–68%, whereas the number of cases 
decreased by 67%: from 6.6 per 1,000 patients in 2006–2007 to 2.2 in 2010
–2011 [5]. In Taiwan, implementation of a national free vaccination program 
led to an increase of vaccination coverage from < 10% before 2003 to 80% 
in 2004; in addition, there was a decrease in the age-standardized incidence 
rates from 7.2 in 2004 to 3.23 cases per 1000 person-years in 2008 [6]. In 
other countries where routine universal vaccination has been implemented, 
studies show significant reduction in the incidence of varicella [2].
     In some countries, however, varicella vaccine still have not been 
adopted into their universal vaccination program due to cost-effectiveness of 
the vaccine and its negative impact on incidence of herpes zoster (HZ). In 
the United Kingdom, a study suggested when introducing a vaccine for 
routine childhood vaccination, there may an upward shift in age distribution 
of varicella, causing more severe disease burden [7]. In addition, a study 
suggested that implementation of universal varicella vaccination in children 
linked to an increased incidence of HZ in older populations [8].
1-2. Epidemiology of varicella and vaccination program in Republic of
Korea 
     In Korea, varicella has become nationally notifiable since July 2005, 
by the time one-dose of varicella vaccine was introduced to national 
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immunization program and recommended for children aged 12-15 months 
old. Varicella vaccination was first started in private clinics for a high-risk 
group and some children after adoption of the vaccine in 1996. Considering 
an average of 600,000 doses per year was approved for market, about 
480,000 to 1,280,000 person was estimated to have been administered 
varicella vaccine in private clinics. In January 2005, a one dose mandatory 
varicella vaccination was introduced to the national immunization program 
and was recommended for 12 to 15 month-old-infants. In 13th July 2005, 
varicella was listed on the national notifiable infectious disease, an 
approximate of 90,000 children from low-income families were administered 
a one-dose varicella vaccine by public health centers. With an assumption 
that the notification rate was 10 percent, a total of 210,000 were estimated 
to have varicella vaccination [9]. Since May 2009, the varicella vaccination 
program was implemented in private clinics providing subsidy of 30 percent 
of the vaccination cost. In 2014, a one-dose mandatory varicella vaccination 
becomes a totally free and universal program for all children aged 12 to 15 
months old [10].
     According to the National Notifiable Disease Surveillance System, 
incidence of varicella showed upward trend during 2006 to 2017 despite the 
implementation of a routine one-dose varicella vaccination. The incidence 
rate increased from 22.5 per 100,000 persons in 2006 to 154.8 in 2017 
(Fig. 1-1). Given the vaccine coverage has reached up to 98.9% in 2012, 
this increasing trend raises doubt on the effectiveness of the vaccine.
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Figure 1-1. Reported cases of varicella and incidence rate to the National 
Notifiable Disease Surveillance System in the Republic of Korea
     The data on the incidence rate of varicella and the vaccination 
coverage during the period before July 2005 when varicella was listed as a 
national notifiable infectious disease was unavailable. The pediatric sentinel 
surveillance, a sampling surveillance system for infectious disease among 
children, which was established in 2001, was a few available data covering 
the period before July 2005. The surveillance system was founded in June
2001 by voluntary participation of the 198 pediatricians and has been 
monitoring the incidence of infectious diseases which are common among 
children such as varicella. In the system, a private clinic was selected as 
sample with the ratio of 1 pediatrician per 100,000 population at a local 
level, which accounts for around 10 percent of the total number of 
pediatricians in the Korea and the reporting rate was maintained over 80 
percent per annum; a sampled pediatrician voluntarily report to the infectious 
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2001 2002 2003 2004 2005 2006 2007
Varicella cases 6,370 9,244 14,296 13,257 15,165 13,779 14,119
Cases per 100 
patient visits
0.30 0.25 0.28 0.28 0.29 0.26 0.27
disease surveillance team in the Korea Center for infectious Disease control 
and prevention through phone call, fax, or internet every week (until 
Tuesday) and even when having zero patient is reported. According to the 
surveillance system, the reported varicella cases and a part of the weekly 
reporting form is as follow (Fig. 1-2, Table 1-1) [9,11].
Figure 1-2. A part of the weekly reporting form in the pediatric sentinel 
surveillance
Table 1-1. Reported varicella cases and cases per 100 patients visits from 
the pediatric sentinel surveillance, 2001-2007
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    Varicella is one of the national notifiable infectious disease and is 
monitored by mandatory surveillance system in which medical doctor, 
oriental medical doctor, and the head of the public health center or 
commander of a unit belonging to the Army, Navy, or Air Force are 
obliged to report when incidence of the disease. The obliged have to 
immediately report a confirmed or probable case to the head of competent 
public health center and then the case was finally reported to the Korea 
center for infectious Disease control and prevention through the web-based 
reporting system (http://is.cdc.go.kr). The mandatory surveillance system has 
a limitation of a reporting bias; The cases may be under-reported when the 
obliged do not fulfill their duty, and the cases may be over-reported when 
they report a similar symptom as varicella case due to health insurance 
coverage [12].
     In the late 1980s, the Oka strain vaccine manufactured by Biken, 
Japan, was first imported and administered. In the mid 2000s, around the 
time a universal varicella vaccination program was adopted, there are four 
live attenuated vaccines are available; three (Varilrix by GSK, Varivax by 
MSD, Vari-L by Changchun) are imported and based on Oka strain, and 
one (Suduvax by Green Cross) is domestic and based on the MAV strain
which is isolated from a 33-month-old Korean boy in 1989. Until recently, 
Suduvax and Vari-L predominantly used in the Korea and, in 2018, a 
domestic Oka strain based vaccine (Skyvaricella by SK Bioscience) was 
introduced. (Table 1-2)
8
Year Strain Name of product Manufacturer
2006 Oka Varilrix GSK
Vari-L Changchun Institute
Sudu Vaccine CJ
MAV/06 Suduvax Green Cross
Ref) The guidelines for varicella, 2006, KCDC
2008 Oka Varilrix GSK
Varivax MSD
Vari-L Changchun Institute
MAV/06 Suduvax Green Cross
Ref) Varicella Vaccine, Hanyang Medical Reviews Vol.28.No.3.2008.
2014 Oka Vari-L Changchun Institute
Suduvax Green Cross
Ref) The vaccines distributed on the domestic market (as of 2014.7.1), 
2015, KCDC
2018 Oka Vari-L Changchun Institute
Skyvaricella SK Bioscience
MAV/06 Suduvax Green Cross
Ref) The vaccines distributed on the domestic market (as of 2018.9.10.), 
KCDC (http://nip.cdc.go.kr)




     This study was to investigate the changes in the epidemiology of 
varicella since the introduction of varicella vaccination and to evaluate the 
vaccine effectiveness of the national immunization program in Korea. The 
objectives are as follows:
     First, identify the effect of age, period, and birth cohort on increasing 
temporal trend of varicella incidence among children in Korea by conducting 
APC analysis.
     Second, identify spatial patterns in varicella incidence and geographical 
risk factors of the disease by spatial autocorrelation analysis and fitting 
spatial regression model.
     Third, evaluate the effectiveness of universal one-dose vaccination 
program on the incidence of varicella by performing a matched case-control 
study if there is primary or secondary vaccine failure. 
     Finally, assess the effect of varicella vaccination on disease severity 
despite that the vaccination might fail to protect against varicella incidence.
     The investigation of changes in epidemiology of varicella and 
evaluation of national varicella vaccination program may provide guidance 




Increasing varicella incidence rates among children 
in the Republic of Korea
: An Age-Period-Cohort analysis
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2-1. Introduction
     Varicella is an acute infectious disease caused by the varicella-zoster 
virus. It is highly communicable, with secondary attack rates greater than 
90% among susceptible individuals. The varicella vaccine, which became 
available in the early 1980s, conferred excellent immunogenicity against 
varicella infection. Countries such as the United States, Germany, and 
Taiwan where adopted varicella vaccination program experienced reduction in 
incidence rate of varicella [3,5,6].
     In the Republic of Korea, one-dose of varicella vaccination was 
introduced to the National Immunization Program (NIP) in 2005. However, 
the incidence rate of varicella has yet to decline and, in fact, has been 
continuously rising, from 22.5 per 100,000 persons in 2006, to 154.8 in 
2017 [13], despite the vaccine coverage has reached up to 98.9% in 2012 
[14].
     The age, period, and cohort (APC) effects may provide important 
epidemiologic clue to elucidate the current gap in immunity. Age effects are 
associated with different age groups, period effects affect all ages 
simultaneously over time, while cohort effects are related to changes among 
groups of individuals born in the same year. For instance, age effects imply 
the biological susceptibility of people of a specific age, period effects reflect 
environmental changes or diagnostic efficiency, and cohort effects represent 
early exposure to risk factors. The APC analysis has been used to study 
time trends in the incidence of infectious diseases [15-18]. The model 
separates time trends into the effects of age, period, and cohort. 
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     In this study, we used APC model to obtain a better understanding of 
these effects on the incidence of varicella in Korea. The results might 
provide guidance for future epidemiological research and may implicate for 
better surveillance and vaccination policies.
2-2. Materials and Methods
Data collection
     In Korea, varicella has become nationally notifiable since July 2005. 
In this study, to use full-year data on the annual varicella incidence, we 
obtained the National Notifiable Disease Surveillance System data from 
January 2006 to December 2017. Population statistics were available from 
the Korean National Statistics Office. The person-years of observation were 
tabulated into one-year classes for ages 0–12 and for the calendar period 
2006–2017.
Statistical analysis
     The APC model was used to estimate the age, period, and cohort 
effects. The standard APC model assumes that the observed number of 
varicella infections follows a Poisson distribution and that the incidence rates 
are a multiplicative function of age, cohort, and period, such that the 
logarithm of the rates is an additive function of the parameters [19-22]. The 
log age-specific rate λ (a,p) at age a in period p for people in cohort 
c=p-a, is as follows:
log[λ(a,p)] = f(a) + g(p) + h(c)
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where a, p, and c denote the mean age, period, and cohort, respectively, for 
the observational units and f, g, and h are parametric functions. The exact 
linear dependence of the regression variables (c=p-a) causes identifiability 
problem [22]. To decompose these three components into linear and 
non-linear parts and to obtain estimable functions such as the log-linear 
trend by period and cohort, we adopted the APC models proposed by 
Rosenberg [23], and conducted APC analysis by the APC Web Tool [24].
     This online web tools provides “net drift”, indicates the annual 
percentage change of the expected age-adjusted rates over time (period and 
cohort); “local drift”, the annual percentage change of the expected 
age-specific rates over time; “longitudinal age curve”, the expected 
age-specific rates in reference cohort adjusted for period effects; “period (or 
cohort) rate ratio (RR)”, the age-adjusted relative risk in each period (or 




     Varicella incidence and age-standardized incidence rates have shown a 
diagonally upward trend between 2006 and 2017 (Fig. 2-1A). The incidence 
rate stratified by period also increased for almost all age groups (0 to 12–
year–old). And the rates peaked between ages 4 and 6 years and we 
observed a drop-off in older ages (Fig. 2-1B).
     An increasing tendency of higher varicella incidence rates with later 
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periods was determined for each age group (Fig. 2-2A). The age at which 
peak of incidence rate shifted from 4 years of age during 2006–2009, to 5 
during 2010–2012, and to 6 during 2013–2017(except in 2016), which 
reflecting an age shift. The cohort curves also showed an increasing trend 
with later birth cohorts, especially, in ages 5 and 6 years (Fig. 2-2B). The 




Figure 2-1. (A) Age-standardized incidence rates of varicella, 2006–2017 (B) 




Figure 2-2. (A) Age-specific incidence rates of varicella by period, 2006–2017
(B) Age-specific incidence rates of varicella by birth cohort, 2001–2012.
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Age-period-cohort analysis
     The age, period, and cohort effects are presented in Fig. 2-3 and 2-4. 
The longitudinal age curve of varicella incidence rate displays the risk 
increased to peak at the ages 6–7 years and then declined thereafter (Fig. 
2-3). The net drift, which indicate the annual percentage change of the 
estimated age-adjusted rates over time, was 17.4 and the curves of local 
drift, which reflect the annual percentage change of the estimated 
age-specific rates over time, showed upward trend with a peak at the age of 
10–11 years.
     The estimated period and cohort rate ratios (RRs) showed similar 
increasing patterns, however, period RR dramatically elevated in 2017 while 
cohort RR slightly decreased after the year 2015 (Fig. 2-4). 
     Wald tests suggested both period and cohort effects were statistically 
significant (P < 0.05 for all).
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Figure 2-3. Longitudinal age curve and drifts(net drift and local drifts) 
obtained age-period-cohort analyses for the incidence rate of varicella and 
the corresponding 95% confidence intervals, 2006–2017.
19
Figure 2-4. Period and cohort effects obtained age-period-cohort analyses for 




     Despite implementation of the universal varicella vaccination program 
in July 2005, there was an increase in the incidence rate of varicella 
between 2006 and 2017 in Korea. Our finding demonstrated that the period 
and cohort effects showed an upward trend over time except the age peak 
in the incidence rate shifting from 4 to 6 years old. This may indicate that 
a universal one–dose varicella vaccination in Korea has not been successful 
in preventing varicella zoster virus.
     These the finding contradict to the observations in other countries. In 
the US, routine one–dose vaccination of all children between the ages of 12 
and 18 months was implemented in 1996 and has resulted in decreases in 
the incidence from 1.1–3.8 cases per 1,000 population between 1990 and 
1994 to 0.3–1.0 cases between 1999 and 2001 [3]. The vaccine effectiveness 
of one-dose vaccination was estimated to be 85% (95% CI: 78–90%; p < 
0.001) [4]. Elsewhere, introduction of one–dose vaccine to the NIPs has led 
to decreases in the incidence even when vaccination coverage is suboptimal. 
In Germany, where a routine varicella vaccination program was introduced 
in 2004, vaccination coverage between 2006 and 2011 was only 38–68%, 
whereas the number of cases decreased by 67%: from 6.6 per 1,000 patients 
in 2006–2007 to 2.2 in 2010–2011 [5]. In Taiwan, implementation of a 
national free vaccination program led to an increase of vaccination coverage 
from < 10% before 2003 to 80% in 2004; in addition, there was a decrease 
in the age-standardized incidence rates from 7.2 in 2004 to 3.23 cases per 
1000 person-years in 2008 [6]. 
     Our data may be explained by primary or/and secondary vaccine 
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failure. Primary failure relates to the failed mounting of the immune system 
to produce antibodies initially [25]. A prospective case-based study 
conducted from 2006 to 2007 in Korea, showed almost no impact of 
varicella vaccine introduction, possibly due to insufficient immunogenicity 
[26]. The vaccine immunogenicity estimated in the case-control study was 
54% (95% CI, 0.10–2.05), and the classical fluorescent antibody to 
membrane antigen (FAMA) assay revealed the seroconversion rate was 
76.7%.
     Secondary failure refers to the waning of vaccine-induced immunity 
over time [25]. Recent studies suggest that one-dose varicella vaccination 
have limited effectiveness to prevent outbreaks in mass gatherings or 
schools. In the U.S., after the introduction of varicella vaccine, there was a 
substantial difference in the vaccine's effectiveness in the first year after 
vaccination (97%) and in years 2 to 8 after vaccination (84%, P =.003) 
[27]. Another retrospective cohort study involving students attending 
elementary school suggested that 99% of one-dose vaccination coverage was 
not sufficient to prevent the varicella outbreak [28]. A longitudinal 
seroprevalence study in Korea showed a progressive decrease of the 
seropositivity rates following vaccination: 65% at age 1 year, 59% at age 2 
years, 53% at age 3 years, and 49% at age 4 years [29]. The decreasing 
trend of antibody level may explain the continuing increase of varicella in 
all given cohorts despite the introduction of the vaccine into the national 
immunization program. According to Lee et al. [30] varicella vaccine 
effectiveness in Korea sharply declined after the three year of vaccination. 
Considering Korea’s high rate of vaccine coverage, most of the varicella 
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incidence is associated with breakthrough case. The age peak shifting 
detected in Korea, in spite of a rise in the incidence rate of varicella, could 
be associated with secondary failure. The age shift usually occurs with a 
decrease in the incidence rate because one-dose varicella vaccine applied to 
younger children about 12-18 months of age reduces exposure to circulating 
varicella zoster virus. The varicella vaccine, however, is merely effective in 
the early years, but, in later, the incidence of breakthrough infection jumps 
as immunity rapidly wanes over time. 
     Historical context is important in interpreting the data. In Korea, a 
varicella vaccine was first licensed and distributed in private market since 
1988 [31]. There is no accurate data on vaccine coverage rate in the 1990s, 
but given the annual production volume over 500,000 doses, which is larger 
than the annual birth cohort of 400,000–500,000 the one dose coverage rate 
may have been sustained for more than decades. The first survey to 
measure vaccination coverage for varicella at regional rates was conducted in 
2000 and was based on 850 children for whom vaccination record books 
were available. The survey revealed an overall varicella vaccination coverage 
of 72.5% [32]. In a subsequent coverage study, carried out in 2012 by 
face-to-face interview-based questionnaire survey among randomly selected 
3,393 children aged 19-83 months, coverage with the one-dose varicella 
vaccine was 98.9% [33]. Given the high vaccination coverage in Koreans 
prior to the introduction to the NIP, the program may have not impacted in 
the incidence of varicella greatly.
     Our study had a limitation that the period effect may have reflected 
registration bias. First, national surveillance of varicella was started in 2005, 
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by the time varicella vaccine was introduced to NIP; thus, the reporting 
system may not have been fully active during its initial stages, causing 
reporting bias. Second, given the nature of passive surveillance, a large 
portion of cases may be under reported especially those with mild 
breakthrough infections. In addition, lack of the incidence data before the 
implementation of one-dose varicella vaccine program made it hard to 
evaluate the exact effectiveness of the vaccination program. Despite these 
limitations, the present study is unique to evaluate the APC effects in a 
national varicella vaccination program. Our data indicate that individuals in 
the all cohorts, as well as more recently born cohorts have higher incidence 
of varicella infection, signaling a potential need for investigation on the gap 
of immunity.
     In conclusion, there has been increase in the incidence of varicella 
among the Korean population with age peak shifting from 4 to 6 years old. 
Our data suggest the need for additional studies to address the current gap 
in varicella vaccination program in Korea.
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CHAPTER 3.
Spatial epidemic characteristics and risk factor 
analysis of varicella in the Republic of Korea
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3-1. Introduction
     Varicella is an acute infectious disease caused by the varicella-zoster 
virus. The virus spreads mainly by touching or breathing in the virus 
particles that come from chickenpox blisters, and possibly through tiny 
droplets from infected people that get into the air after they breathe or talk, 
for example [34].
     Countries such as the United States, Germany, and Taiwan where 
adopted varicella vaccination program experienced reduction in incidence rate 
of varicella [3,6,35]. The Republic of Korea, however, in spite of adoption 
of one-dose of varicella vaccination for children aged 12-15 month, its 
incidence rate showed an upward trend from 22.5 cases per 100,000 persons 
in 2006 to 154.8 cases in 2017 [36].
     The geographic differences in varicella outbreak have not been 
assessed previously. As varicella tend to cluster geographically where 
susceptible population reside in close proximity, spatial analyses may provide 
better understanding to predict the incidence pattern of varicella. In this 
study, we used descriptive GIS methods and conducted spatial regression 
analysis to depict the spatial characteristics of varicella in Korea and to 
detect risk factors for varicella incidence at local level.
3-2. Materials and Methods
Data collection
     The Republic of Korea is located in southern part of Korean Peninsula 
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and covers an area of 100,032km2 with population of around 52 million in 
2017. It consists of 17 provinces (si-do) divided into 250 districts 
(si-gun-gu). In this study, a total of 250 districts were included for spatial 
analysis. 
     In Korea, varicella has become nationally notifiable since July 2005. 
To collect the number of reported varicella cases at district level from 
January 2006 to December 2017, we used the National Notifiable Disease 
Surveillance System. Sociodemographic data on population density, childhood 
percentage, number of hospitals per 1,000 person, and vaccine coverage rate
for each district were available from the Korean National Statistics Office. 
Direct standardization was used to derive varicella incidence rate for each 
districts.
Statistical analysis
     An epidemic curve of monthly varicella cases during January 2006 to 
December 2017 was drawn to reveal the seasonal peaks and annual 
incidence was plotted to identify the annual trend during the periods.
     To examine spatial distribution of incidence rates and their spatial 
autocorrelation, we visualized incidence rates divided into ten color scales 
between districts and calculated Moran’s Index. To find local clusters such 
as ‘hot spots’ (high values next to high, HH), and ‘cold spots’ (low values 
next to low, LL), local indicators of spatial association (LISA) analysis was 
performed. Monte Carlo simulation was used to evaluate the p-value in 
conducting LISA analysis.
     A spatial regression analysis was performed to find sociodemographic 
27
Y=ρWY+Xβ+ε
predictors of varicella incidence to district level. The spatial lag and spatial 
error model is an extension of the traditional ordinary least square (OLS) 
regression model to include spatial dependency of variables or errors in the 
model. The spatial lag model takes the form:
Where values of the dependent variable in neighboring locations () are 
included as an extra explanatory variable. The spatial error model takes the 
form:
Y=Xβ+λWε+u
Where values of the residuals in neighboring locations () are included as 
an extra term in the equation. For the lack of predictors in 2017 and 
smoothing varicella incidence according to annual time trend, we focused on 
the last 6 years of the surveillance period (2012–2017).
     We used GeoDa software (version 1.12, The University of Chicago, 
IL, USA) to conduct spatial analyses and QGIS software (version 3.2.1) to 
visualize maps of incidence rates and local clusters.
3-3. Results
Temporal trend
     An increasing tendency of annual varicella incidence was observed 
during the whole 12-year period with a surge in 2017 (26,032 cases 
increased than the previous year) (Fig. 3-1A). During the period, varicella 
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incidence rapidly increased from 11,027 cases in 2006 to 80,092 cases in 
2017 except small and large dips in 2010 (797 cases decreased than the 
previous year) and 2012 (8,486 cases decreased than the previous year), 
respectively. The monthly distribution of varicella cases showed a clear 
seasonal pattern with two peaks (Fig. 3-1B). The higher peak occurred in 
December and the lower peak occurred in May and the both of them fall 




Figure. 3-1. Annual trend in varicella incidence during 2006-2017 and 
epidemic curve of monthly varicella cases in the Republic of Korea, 




     Varicella incidence cases distributed at 250 districts during the
surveillance years were summerized in the following table (Table 3-1) being 
categorized into 17 provinces (si-do) (Fig. 3-2).
Table 3-1. Geographical distribution of varicella cases during 2006–2017 in 
the republic of Korea
Province
(No. of districts)
2006–2008 2009–2011 2012–2014 2015–2017
N (%) N (%) N (%) N (%)
Total(250) 50,967 (100.0) 81,641 (100.0) 106,979 (100.0) 179,920 (100.0)
Seoul(25) 4,390 (8.6) 8,032 (9.8) 11,641 (10.9) 21,864 (12.2)
Busan(16) 6,323 (12.4) 8,942 (11.0) 8,138 (7.6) 9,934 (5.5)
Daegu(8) 3,798 (7.5) 7,927 (9.7) 7,174 (6.7) 9,458 (5.3)
Incheon(10) 4,923 (9.7) 7,370 (9.0) 7,869 (7.4) 10,406 (5.8)
Gwangju(5) 1,005 (2.0) 1,917 (2.3) 2,828 (2.6) 5,532 (3.1)
Daejeon(5) 937 (1.8) 1,913 (2.3) 2,352 (2.2) 5,686 (3.2)
Ulsan(5) 2,677 (5.3) 3,112 (3.8) 3,760 (3.5) 5,525 (3.1)
Gyeonggi(42) 12,041 (23.6) 18,356 (22.5) 28,812 (26.9) 50,580 (28.1)
Sejong(1) 0 (0.0) 0 (0.0) 128 (0.1) 1,246 (0.7)
Gangwon(18) 6,228 (12.2) 7,945 (9.7) 6,339 (5.9) 5,397 (3.0)
Chungbuk(14) 1,010 (2.0) 2,039 (2.5) 1,807 (1.7) 4,008 (2.2)
Chungnam(16) 349 (0.7) 1,981 (2.4) 4,994 (4.7) 7,200 (4.0)
Jeonbuk(15) 1,556 (3.1) 1,087 (1.3) 4,946 (4.6) 7,851 (4.4)
Jeonnam(22) 1,210 (2.4) 2,408 (2.9) 4,059 (3.8) 8,130 (4.5)
Gyeongbuk(24) 2,203 (4.3) 3,011 (3.7) 3,753 (3.5) 8,707 (4.8)
Gyeongnam(22) 938 (1.8) 2,870 (3.5) 5,984 (5.6) 14,540 (8.1)



















Figure 3-2. The map of 17 provinces in the Republic of Korea.
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     Varicella incidence rates of 250 districts according to surveillance 
years were described in color scaled maps with bold border line among 17 
provinces (si-do) (Fig. 3-3). During the early surveillance periods of 2006–
2008, there were concentrated regional distributions of outbreak in northeast 
(Gangwon-do) and south (Jeju-do) part of the country, where remote places 
from metropolitan city and located in rural area. During the second 
surveillance periods of 2009–2011, varicella incidence slowly spread out 
from northeast to its neighboring regions (Gyeonggi-do and 
Chungcheongbuk-do). During the third surveillance periods of 2012–2014, 
the increase of incidence rate was noted across the country. During the last 
surveillance periods of 2015–2017, a nationwide high incidence of varicella 
was reported and the high incidence region moved to central north 
(Yongin-si) and the edge of southwest (Mokpo-si) and southeast (Busan) 
part of the country. 
     The spatial pattern of clustering for varicella incidence rate was 
observed through global autocorrelation analysis (Table 3-2). A clear positive 
spatial autocorrelation was found within the varicella incidence rate during 
the whole periods of surveillance. Moran’s Indices ranged from 0.1400 to 
0.3210 and were all significant. 
     Local spatial clusters were shown in color categorized maps (Fig. 3-4). 
During the periods of 2006–2014, the High-High (HH) clusters were mostly 
confined to northeast region (Gangwon-do) and its neighboring districts 
(Yongin-si, Yeoju-si, Ichon-gun, Yangpyeon-gun in Gyeonggi-do). The 
neighboring districts also showed ‘hot spot’ clusters during the last 
surveillance periods of 2015–2017. The Low-Low (LL) clusters were mostly 
distributed southern part of the country during the surveillance periods. In 






Figure 3-3. Incidence rate per 100,000/year of varicella in the Republic of 
Korea, 2006–2017.
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　 Moran’s Index Z p value
2006 0.1400 2.6566 0.019
2007 0.2443 4.9754 0.001
2008 0.2245 4.6494 0.001
2009 0.1894 3.7468 0.003
2010 0.3210 6.258 0.001
2011 0.2102 4.0321 0.003
2012 0.2880 5.393 0.001
2013 0.2768 5.285 0.001
2014 0.2201 4.2282 0.001
2015 0.1921 3.7084 0.002
2016 0.1939 3.6515 0.002
2017 0.2491 4.7742 0.001
Table 3-2. Global spatial autocorrelation analysis of varicella incidence in 










     We assumed that sociodemographic factors such as population density, 
childhood (0 to 12-year-old) percentage, number of hospitals per 1,000 
person, and vaccine coverage rate have influenced epidemics of varicella 
disease at district level (Table 3-3). Vaccine coverage rate of each provinces 
was over 96% and its geographical distribution was depicted in the map 
(Fig. 3-5). Using those variable as predictors, with annual varicella incidence 
as the dependent variable, we fitted a spatial regression model. Spatial error 
dependence resulted statistically significant and it could interpret 36.6% of 
the total variation (Table 3-4) while spatial lag dependence did not. 
Population density and number of hospitals per 1,000 person which is a 
proxy for local health infrastructure resulted having negative coefficient and 
the former was statistically significant. Childhood percentage had a positive 
coefficient and was statistically significant while vaccine coverage rate,
which was categorized into four ordinal values by quartile of its distribution
to avoid multicollinearity problem, resulted having positive coeffcient and
statistically insignificant.
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Figure 3-5. Map of average of vaccination coverage rates in the Republic of 
Korea, 2015–2017.
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Table 3-3. Varicella incidence rate and sociodemographic predictors during 













h osp i t a l s
(per 1,000)
v a c c i n e 
coverage 
rate(%)
Total(250) 93.5 511.9 11.9 1.7 97.3
Seoul(25) 55.7 16653.8 10.4 2.1 96.2
Busan(16) 85.0 4571.9 10.0 1.8 96.8
Daegu(8) 111.0 2823.3 11.4 1.9 97.6
Incheon(10) 104.9 2765.7 12.2 1.4 97.7
Gwangju(5) 94.7 2936.8 13.4 1.8 98.2
Daejeon(5) 88.0 2824.8 12.9 1.9 97.7
Ulsan(5) 133.1 1096.7 13.0 1.5 98.4
Gyeonggi(42) 104.3 363.7 8.9 1.4 98.3
Sejong(1) 108.0 1217.2 13.2 1.5 97.4
Gangwon(18) 126.9 91.9 11.0 1.5 97.9
Chungbuk(14) 65.5 213.1 14.1 1.8 98.1
Chungnam(16) 98.2 251.2 12.5 1.6 98.0
Jeonbuk(15) 114.2 231.9 11.7 1.9 97.7
Jeonnam(22) 106.7 155.0 11.1 1.7 98.0
Gyeongbuk(24) 76.8 141.9 11.0 1.6 97.8
Gyeongnam(22) 102.2 317.8 12.6 1.4 97.7
Jeju(2) 168.8 330.0 13.6 1.7 97.0
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Table 3-4. Spatial regression of sociodemographic predictors of varicella 
incidence in the Republic of Korea, 2012–2017
Variable* Coeff. S.E. P value AIC R-squared
Constant 59.4212 12.5438 0.0000
2491.9 0.3658
Population Density -0.0010 0.0005 0.0352
Childhood Percentage 321.25 83.276 0.0001






Lambda 0.4731 0.0546 0.0000
* Data of sociodemographic predictors in 2017 were missing and vaccine coverages were only
available during 2015–2017. Spatial error model was fitted.
† Vaccine coverage quartile(min: 0.9363, Q1: 0.9697, Q2: 0.9758, Q3: 0.9800, max: 0.9897) 
was used to avoid multicollinearity problem.
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3-4. Discussion
     In this study, varicella epidemics varied over time and space. Our 
finding demonstrated that a temporal uptrend of varicella incidence in Korea 
from 2006 to 2017 and High-high positive spatial associations confined in 
northeast region (Gangwon-do) and their neighboring districts gradually 
spread and faded out over time, which led overall increase in varicella 
incidence across the country. In spatial regression analysis, childhood 
percentage has positive effect on the incidence of varicella at district level 
while population density and number of hospitals per 1,000 person have 
negative effect.
     An upward trend in varicella incidence in Korea despite adoption of a 
universal one-dose vaccination is consistent with previous studies. Those 
studies suggested that an insufficient immunogenicity of the vaccine might 
have limited effectiveness to decrease in the incidence of varicella. In a 
population-based study, the effectiveness of the varicella vaccine was 13% 
(95% CI:-17.3–35.6) and the immunity rapidly waned three years after the 
vaccination [30]. Furthermore, a population-based study on effects of 
one-dose varicella vaccination on disease severity suggested one-dose 
varicella vaccination resulted milder symptoms leading to a failure to isolate 
patients and ended up outbreaks among those in close contact such as 
children in kindergarten or elementary school [37].
     There was no study on spatial epidemic characteristics of varicella 
incidence at nation-wide scale. Nevertheless, an occurrence of local 
‘hot-spots’ in remote areas such as Gangwon-do may be similar to the 
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results from other studies at province scale or focusing on other respiratory 
diseases like mumps and measles. In a spatio-temporal analysis of varicella 
in Valencia, Spain from 2008 to 2012, spatio-temporal clusters were 
identified where the population is economically disadvantaged or perhaps less 
educated and less aware of vaccination schedules [38]. In spatio-temporal 
analysis of measles [39] and mumps [40] in China, high-risk clusters were 
mainly distributed in the urban-rural transition zones or semi-urban areas 
because, with parents migrating to urban areas for employment opportunities, 
children were left in impoverished and remote area from vaccination clinics 
and became susceptible to disease.
     The spatial regression results revealed that childhood percentage, which 
is population at high risk, had influence on the incidence of varicella. In the 
present study, childhood percentage showed vulnerability to varicella 
outbreak. This is in accordance with a previous study conducted APC 
analysis of varicella incidence in Korea [41], where the peak incidence was 
found at 4 to 6 years of age. In spatial analysis of mump in Korea, 
proportion of children population was a significant risk factor of mumps 
incidence because children were more susceptible than other age groups in 
population [42].
     Number of hospitals per 1,000 person in district, considered as factor 
for health infrastructure in this study, also had effects on the incidence of 
varicella though statistically insignificant with p-value of 0.0693. The less 
healthcare providers had the district, the more had varicella incidence. This 
factor may be associated with low economic status of the district and be in 
line with the result of spatial analysis noted above.
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     The irrelevance of vaccine coverage rate to the incidence of varicella
may be accounted by its value itself being higher than 90%, ranging from 
92.3% to 100%. Given the high vaccination coverage in Koreans prior to
the introduction of a universal one-dose varicella vaccination in 2005 and 
reached up to 98.9% in 2012, the vaccine may have not impacted in the 
incidence of varicella greatly.
     Our study had several limitations. First, varicella cases were not 
collected from passive surveillance system, which cannot exclude reporting 
bias. A large portion of cases may be under reported especially those with 
mild breakthrough infections. Second, varicella cases were derived from 
aggregated data at district level not from individuals because of 
inaccessibility of personal information. Factors such as vaccination coverage, 
disease severity, and other socioeconomic status at individual level that may 
drive the varicella epidemic were not included in spatial regression model 
and have yet to be examined in detail. Finally, there might be 
multicollinearity among predictors of varicella incidence. We included popula
tion density, childhood percentage, number of hospitals per 1,000 person, 
and vaccine coverage rate at once as independent variable. Thus, a flaw 
may exist in the interpretation of the causal relationship of the disease. 
Despite these limitations, this study is the first study to describe the spatial 
epidemiological characteristics of varicella by using spatial analysis at the 
district level in Korea and identified high-risk clusters and risk factors.
     In conclusion, we intended to demonstrate the temporal and spatial 
pattern of varicella in the Republic of Korea during the past 12 years. Our 
study indicates that varicella incidence according to geographic regions vary 
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by population density, childhood percentage in the district and neighboring 
regions, suggesting the importance of community-level surveillance and 
monitoring strategy to prevent and control varicella incidence.
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CHAPTER 4.
Effectiveness of varicella vaccination program in 
preventing laboratory-confirmed cases in children in 
Seoul, the Republic of Korea
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4-1. Introduction
     Varicella is an acute contagious disease caused by the varicella-zoster 
virus (VZV). A live attenuated varicella vaccine was first developed in 1974 
and is now used widely in many countries including the United States, 
Germany, China, Taiwan, and Republic of Korea [43-47]. In a recent 
meta-analysis of global varicella vaccine effectiveness, varicella vaccine was 
reported to be effective in preventing varicella [48]. In specific, the United 
States where a universal two-dose varicella vaccination program was adopted 
since 2006 experienced declines in the incidence of the disease, the 
hospitalization of infected patients, and disease outbreaks [49].
     In Republic of Korea, the varicella vaccination has been recommended 
for children in high-risk groups since 1988. Following the introduction of 
universal varicella vaccination by the National Immunization Program (NIP) 
in 2005, one-dose varicella vaccine has been recommended for all children 
aged 12–15 months. Four live attenuated varicella vaccines are available; 
three are based on the Oka strain, and one is based on the MAV strain. 
However, the incidence of varicella has yet to decline and, in fact, has been 
continuously rising, from 22.5 per 100,000 persons in 2006 to 73.2 in 2013 
[50].
     The objective of this study was to evaluate the effectiveness of 
one-dose varicella vaccination program in Republic of Korea by performing 
a matched case-control on children in Seoul.
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4-2. Materials and Methods
     We performed a matched case-control study on children who were 
younger than 12 years of age in Seoul, Republic of Korea. Relevant data 
were collected from the National Notifiable Disease Surveillance System 
(NNDSS). The NNDSS, which was established in 2001, consists of 
case-based national infectious disease data collected via a surveillance 
system; nationally notifiable diseases such as varicella must be reported by 
all local public health centers in the country. The varicella case data in the 
NNDSS include demographic and clinical details such as patient name, date 
of birth, gender, address, date of disease onset, laboratory confirmation, and 
vaccination status.
     All cases were children with varicella identified in Seoul between 
January 2013 and December 2013. Cases were composed of confirmed and 
possible cases and we only use the former to avoid misclassification bias. 
We excluded cases born prior to universal varicella vaccination adopted in 
2004 or after 2012, because varicella vaccination is recommended for 
children aged 12–15 months. In order to estimate the exact effectiveness of 
varicella vaccine, we also excluded subjects who developed varicella within 
42 days after vaccination (the so-called “wild-type” varicella) and who were 
vaccinated twice.
     We aimed at selecting controls to represent the source population from 
which varicella cases arose. From the same NNDSS data, mumps and scarlet 
fever were considered appropriate as controls for the following reasons; 1) 
mumps and scarlet fever are infectious diseases independent of varicella, 2) 
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age distribution in incidence of mumps or scarlet fever is similar to that of 
varicella.
     In recruiting age-matched controls who had suffered from mumps or 
scarlet fever but had no history of varicella were identified in Seoul 
between January 2013 and December 2013 in the same NNDSS population 
where cases were reported. We matched each control by date of birth to a 
1-month interval centered on the birth date of each case; a single control 
was randomly chosen if more than one candidate seemed appropriate. 
Ultimately, we created a list of 1:1 individually matched controls.
     The effectiveness of a vaccine was estimated as follows; we calculated 
vaccine effectiveness by substituting the matched overall risk (OR) for the 
relative risk (RR) (1–RR); this approximates the RR in a case-control study [51].
Statistical analysis
The  test was used to compare the groups in terms of categorical 
variables, and the paired t-test was used to compare them with regard to 
continuous variables. To estimate the effectiveness of one-dose vaccination, 
we performed conditional logistic regression analysis on the 1:1 matched 
pairs after adjusting for the effects of possible confounders such as sex and 
age at vaccination; we then calculated matched odds ratios with 95% 
confidence intervals (CIs). When calculating the effect of time since 
vaccination, we used conditional logistic models with dummy-coded variables 
[52]. A two-sided P value < 0.05 was considered statistically significant. All 
data were analyzed with the aid of SAS software, version 9.3 (SAS 




     In 2013, a total of 3,622 cases were reported. Of the 3,622, we 
excluded 2,807 possible varicella cases. Of the remaining 815 cases, we also 
excluded 278 cases; 230 had been born before June 2004, 27 had been 
infected within 12 months of birth, 5 had wild-type varicella, 16 had 
received two doses of vaccine (Fig. 4-1). Finally, we included 537 varicella 
cases in the study.
Figure 4-1. Subject recruitment procedures for 1:1 matched case-control 
study.
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Characteristics of cases and controls
     The 537 cases and their individually matched controls were similar in 
terms of both age and gender. The proportions of vaccinated cases and 
controls were similar, at 407 (75.8%) and 419 (78.0%), respectively (Table 1).
     Of those who were vaccinated, 379/407 (93.1%) cases and 366/419 
(87.4%) controls were vaccinated before 15 months of age, as recommended 
by the national vaccination policy. The proportion of cases vaccinated was 
significantly higher than the proportion of controls vaccinated (P < 0.002).
     More than half of all vaccinated cases (241/407; 59.2%) and 227/419 
(54.2%) of the controls received vaccine A; the proportions of the other 
vaccines used were as follows: Unknown (20.4% of cases and 19.1% of 
controls) > vaccine B (13.0% and 10.0%, respectively) > vaccine C (5.9% 
and 11.7%, respectively) > vaccine D (1.5% and 5%, respectively). 
However, the proportions of the vaccines used were significantly different 
between the groups (P = 0.001). Thus, both age at vaccination and type of 
vaccination were entered into the conditional logistic model.
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Characteristics Cases Controls p-value
Age(month) 0.967
  Mean±SD 68.6±22.7 68.5±22.7
  Median(range) 70 (55-85) 70 (54-85)
Gender(no,%) 0.297
  Male 289 (53.8) 306 (57.0)
  Female 248 (46.2) 231 (43.0)
MMR vaccine status(no,%) <.0001
  Unvaccinated 97 (18.1) 13 (2.4)
  Received MMR vaccine 440 (81.9) 524 (97.6)
  No. of varicella vaccination
  within 28days of MMR vaccine
1 (0.19) 3 (0.56)
Vaccination status(no,%) 0.385
  Unvaccinated 130 (24.2) 118 (22.0)
  Vaccinated 407 (75.8) 419 (78.0)
    Age at vaccination(month) 0.002
     ≤15 379 (93.1) 366 (87.4)
     > 15 28 (6.9) 53 (12.6)
    Type of vaccination 0.001
      A 241 (59.2) 227 (54.2)
      B 53 (13.0) 42 (10.0)
      C 24 (5.9) 49 (11.7)
      D 6 (1.5) 21 (5.0)
      Unknown 83 (20.4) 80 (19.1)
Table 4-1. Characteristics of children with varicella and matched controls








Vaccinated 327 80 13.0(-17.3–35.6) 0.361
Unvaccinated 92 38
Effectiveness of varicella vaccination
     According to the conditional logistic regression analysis of the data for 
matched pairs, the overall effectiveness of one-dose varicella vaccination was 
13% (95% CI, -17.3–35.6). The unadjusted estimate of vaccine effectiveness 
was 11.8% (95% CI, -17.1–33.6, P = 0.385) (Table 4-2).
Table 4-2. Overall effectiveness of varicella vaccine
* When unadjusted for matched pairs, vaccine’s effectiveness(1-OR) was 11.8%(-17.1%–
33.6%, p-value=0.385). In addition, when using relative risk(RR) obtained from age 
controlled poisson regression model with robust standard errors, VE(1-RR) was
0.47%(-3.77%–6.75%, p-value=0.8863). When using excess relative risk(ERR), VE was
12.2%(-18.9%–30.0%, not significant under α=0.05).
† VE=vaccine effectiveness(1-matched OR), CI=confidence interval, OR=overall risk. 
     Conditional logistic regression analysis of vaccine effectiveness by each 
of the four vaccine manufacturers showed that the effectiveness of different 
vaccines varied (Table 4-3). Only vaccine C exhibited statistically significant 
effectiveness (88.9%; 95% CI, 52.1–97.4). The vaccine effectiveness were -5
% (95% CI, -61.9–31.9) for vaccine A, -100% (95% CI, -700–50.1) for 
vaccine B, 71.4% (95% CI, -37.5–94.1) for vaccine D, and -16.7% (95% 












A 42 40 -5 (-61.9–31.9) 0.825
B 6 3 -100 (-700–50.0) 0.327
C 2 18 88.9 (52.1–97.4) 0.003
D 2 7 71.4 (-37.5–94.1) 0.118
Unknown 28 24 -16.7 (-101–32.4) 0.580
Table 4-3. Effectiveness of varicella vaccine by manufacturers
     Overall, the effectiveness of a one-dose varicella vaccination was 
75.8% (95% CI, 22.8–92.4) in the first year after vaccination. Thereafter, 
effectiveness decreased, falling to zero (or below) in the fourth and the 
sixth years. When adjusted for sex, age at vaccination and 
measles-mumps-rubella (MMR) vaccination within 28 days of birth, the 
effectiveness of varicella vaccine was not significant even in the first year 



































































Table 4-4. Overall effectiveness of varicella vaccination by time since 
vaccination
* VE=vaccine effectiveness, CI=confidence interval, MMR=measles-mumps-rubella.
† Results are adjusted for sex, MMR vaccination within 28 days, age at vaccination.
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4-4. Discussion
     The results of this study show that the overall effectiveness of 
one-dose varicella vaccination in preventing confirmed cases of varicella was 
low and insignificant (13%; 95% CI, -17.3–35.6). Specifically, the vaccine 
effectiveness of vaccine A, which was used in more than half of all 
vaccinations, was -5% (95% CI, -61.9–31.9), whereas vaccine C was highly 
effective (88.9%; 95% CI, -52.1–97.4). Vaccination was effective for only 1 
year (the estimate of 75.8% fell to 67.1% after adjustment for confounders).
     These results are consistent with those of a recent clinical case-control 
study assessing the effectiveness of an MAV strain-based varicella vaccine 
in Republic of Korea [26]. The estimated effectiveness was statistically 
insignificant (54%; 95% CI, -0.10–2.05) and the vaccine may not have 
alleviated clinical symptoms. In contrast, studies in other countries have 
shown that single-dose varicella vaccination was highly effective in terms of 
both reducing the prevalence of varicella and alleviating the symptom 
severity [45,53-55]. Oka strain-based varicella vaccines have been 87% 
effective in the United States [4,27], 86% effective in Germany [53], and 
84% effective in China [45]. In other studies, varicella vaccination remained 
quite effective over time, although some waning was evident after the first 
year [27]. However, vaccine effectiveness then rebounded and persistent 
immunity was evident in some studies.
     In Republic of Korea, more than half of all vaccinees were immunized 
with vaccine A, derived from an MAV/06 strain of varicella isolated from a 
33-month-old Korean boy in 1989 [57,58]. An immunogenicity study and a 
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prelicensing safety study [58-60] showed that the strain was highly 
immunogenic and safe, with a post-vaccination geometric mean titer (GMT) 
of 173.7 and seroconversion rate of 100%. However, two clinical trials 
[61,62] and a recent clinical case-control study [26] showed that the vaccine 
did not ameliorate disease severity and was poorly immunogenic. A recent 
immunogenicity study on MAV and Oka (Vari-L) vaccine showed that the 
MAV vaccine generated higher seropositivity rates and antibody titers than 
the Oka vaccine and provided immunity against VZV, despite waning of 
immunity observed [29]. Not all Oka vaccine in this study, however, were 
effective against VZV, so it cannot directly be interpreted that MAV vaccine 
is effective.
     The age at vaccination may also affect effectiveness, and our cases 
and controls differed significantly in this regard. In the United States, 
children vaccinated at younger than 15 months were at increased risk of 
breakthrough infection of varicella [27]. The proportion of children 
vaccinated at ages younger than 15 months was higher in the case group. 
Nevertheless, when we entered age at vaccination in our conditional model, 
using a dummy variable for time, age was not significant.
     This study had several limitations. Selection bias may have been 
operating when we created our list of controls. The proportions of cases and 
controls who received MMR vaccinations differed, as it was lower in cases 
(81.9%) than in controls (97.6%). However, as Republic of Korea operates a 
universal health insurance system and as MMR vaccination is included in 
that system, the difference between cases and controls is unlikely to have 
introduced any substantial bias. Second, the severity of disease was not 
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recorded. To assess vaccine effectiveness, it is appropriate to ask if the 
vaccine alleviates severity of symptoms aspects of disease, such as fever, 
rash, and number of lesions. Again, we lacked such data. However, this is 
the first community-based matched case-control study on cases confirmed 
both epidemiologically and in the laboratory who underwent one-dose 
varicella vaccination in the Republic of Korea.
     In conclusion, the one-dose varicella vaccination program did not 
clearly protect against varicella. Therefore, it is necessary to further 




Effects of one-dose varicella vaccination 




     Since the introduction of a universal varicella vaccination program, 
countries such as the United States, Germany and Taiwan has experienced 
reduction in incidence rate of varicella [63-65]. However, in the Republic of 
Korea–where one-dose of varicella vaccination recommending for all children 
aged 12-15 months was introduced to the National Immunization Program
(NIP) in 2005 and the coverage has reached up to 98.9% in 2012 [33] the 
incidence rate of varicella has been continuously rising from 22.5 per 
100,000 persons to 154.8 from 2006 to 2017 [66]. Previous study 
demonstrated that the vaccine immunogenicity may be not sufficient to 
provide effective immunity against varicella infection [26,30].
     To our knowledge, there has been no population-based study to assess 
disease severity of varicella cases after adoption of a universal one-dose 
varicella vaccination to the NIP. In this study, we aimed to investigate the 
effect of vaccination on disease severity of varicella.
5-2. Materials and Methods
     In this study, 1,125 varicella cases reported as part of epidemiological
investigation of varicella from January 2015 to December 2017 in Seoul 
Metropolitan City were used. Data was provided by Korea Centers for 
Disease Control and Prevention (KCDC). According to the KCDC guidelines, 
an epidemiological investigation is re-quired if varicella outbreaks including 
index cases occur in more than 5% of students in a classroom within a 
3-week period in schools, kindergartens or day care centers. When varicella 
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outbreak reported, public health centers should conduct an epidemiological
investigation within 3 days, collecting data from the patient’s parent with 
the help of school health teacher. The information includes the name, 
gender, date of birth, date of diagnosis, vaccination status, and related 
clinical symptoms such as of rash (the number skin lesion), fever, headache 
and arthralgia (Fig. 5-1). Varicella-related symptoms were determined by the 
clinical practitioners through physical examination of the patients. Disease 
severity of patients was assessed by the number of skin lesions as used in 
previous study [4,53,67,68]. Mild cases were defined as those having less 
than or equal to 50 skin lesions; moderate cases were defined as those 
having 51-249 skin lesions; severe cases were defined as those having more 
than or equal to 250 skin lesions.
     We excluded 117 cases: 3 cases were excluded for infected before 12 
months of age; 12 cases for having varicella within 42 days after 
vaccination (breakthrough varicella in infection with VZV occurring in a 
vaccinated person more than 42 days after vaccination); 4 cases for being 
2-dose vaccinated; and 98 cases for being born before 2004.
     We used t-test and Chi-square were to compare the difference in 
distribution in general characteristics, clinical symptoms and disease severity 
in the vaccinated (breakthrough) group and unvaccinated group. Binary 
unconditional logistic regression analysis was performed to examine the 
differences in disease severity between the two groups with factor of age 
controlled.
     All statistical analyses were implemented by using SAS software, 
version 9.3 (SAS Institute, Inc., Cary, NC, USA). P<0.05 was considered 
significant and all tests of statistical significance were two-sided. 
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Figure 5-1. Varicella epidemiological investigation reporting form.
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5-3. Results
     Among a total of 1,008 varicella cases in Seoul, Korea, 869 cases 
(86.2%) were breakthrough cases and 139 (13.8%) were unvaccinated cases. 
The mean age for breakthrough cases was younger than unvaccinated cases 
(7.72 y vs 8.82 y; P<0.0001). No significant differences were observed in 
gender and report source distributions in the two groups. Of those cases, 
about a half were male or female and 83 to 88% cases were elementary 
school students.
     There was no difference in the clinical symptoms between the two 
groups. Among patients, rash was the most common in breakthrough group 
and unvaccinated group (99.5 and 100%, P=0.4229) and rash onset on 
mostly on the body (54.1% and 43.7%, P=0.0008); fever was the second 
(33% and 36.7%, P=0.5095); headache was the third (7.3% and 10.1%, 
P=0.2448); arthralgia was the rare (1.2%, only in the breakthrough group).
     Disease severity differed between the two groups. In the breakthrough 
group, the proportion of cases with moderate-to-severe symptoms was less 
than that in the unvaccinated group (14.6% vs 25.8%, P=0.0016). The risk 
for occurrence of moderate-to-severe disease in the breakthrough group was 













  Mean±SD 7.72 ± 1.86 8.82 ± 2.04 <.0001
Gender(no, %)
  Male 478 (55.0) 72 (51.8) 0.4807
  Female 391 (45.0) 67 (48.2)
Report Source(no, %)
  Kindergarten 131 (15.1) 13 (9.4)
  Elementary School 724 (83.3) 122 (87.8)
  Unknown 14 (1.6) 4 (1.6)
Clinical symptoms(no, %)a
  Rash 865 (99.5) 139 (100.0)
   Affected part of rash onset
     Face and neck 333 (38.5) 56 (40.3)
     Body 468 (54.1) 60 (43.2)
     Arms and legs 64 (7.4) 23 (16.5)













104 (74.8)742 (85.4)  Mild(<50)
  Moderate to severe(≥50) 127 (14.6) 35 (25.8)
     Moderate(50-249) 114 (89.8) 32 (91.4)
     Severe(≥250) 13 (10.2) 3 (8.6)
Table 5-1. Comparison of the epidemiology and disease severity between the 
breakthrough cases and unvaccinated cases
* Detected every clinical symptoms were recorded




     The results of the present study showed that one-dose vaccination was 
associated with the attenuation of disease severity in children varicella cases. 
We found that the risk for severe illness was significantly decreased in 
breakthrough group than unvaccinated group (14.6% vs. 25.8%; OR=0.570). 
In other words, the vaccine effectiveness (=1–OR) of one-dose of varicella 
vaccine administered at 12-15 months of age was 43% (95% CI: 11.0–
63.5%) against moderate-to-severe varicella.
     This finding is consistent with results from previous studies reported 
elsewhere. The odds ratio that the illness was more severe than mild in 
breakthrough cases than in unvaccinated cases was noted in Germany 
(12.5% vs. 68.2%; OR=0.183)10, the United States (14.3% vs. 52.4%; 
OR=0.273)9 and in China (25.6% vs. 44.8%; OR=0.446) [68].
     Our data may be contrasted to the results from studies on varicella 
vaccine effectiveness suggesting the insufficient immunogenicity of the 
vaccine in Korea. In a clinical-based study, the effectiveness of one varicella 
vaccine product (Suduvax, Green Cross, South Korea) was estimated 54% 
(CI: 0.10–2.05) by case-control study and the seroconversion rate was 
76.67% by the classical fluorescent antibody to membrane antigen (FAMA) 
assay [26]. In a population-based study in Seoul, Korea, the effectiveness of 
the varicella vaccine was 13% (CI: -17.3–35.6) and the vaccine-induced 
immunity rapidly decreased after three years since vaccination, suggesting 
waning of immunity [30].
     From these findings, we could suggest that a universal one-dose 
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varicella vaccination program may have limited effectiveness to decrease in 
the incidence rate of varicella but have positive effect in attenuation of 
disease severity in children varicella cases. Two clinical studies on the 
severity of varicella in Korea demonstrated that milder pattern of rash was 
observed in breakthrough group than in unvaccinated group [69] and the 
number of lesions detected were significantly lower in breakthrough group 
than in unvaccinated group [62]. From the perspective of a vaccinated 
patient, milder symptoms by attenuation of disease severity are benefit. 
Contrarily, from the perspective of a population health care management, pat
ients with breakthrough varicella can also transmit varicella to others despite 
that they generally have a lower rate of infectivity than those who are 
unvaccinated. Mild symptoms often lead to a failure to isolate patients and 
lead to outbreaks among those in close contact such as children in 
kindergarten or elementary school.
     Our study had several limitations. A relatively small number of 
unvaccinated cases due to a high level of vaccine coverage may cause 
selection bias. A tendency that a patient who is infected with varicella in 
later years develops severe disease could be confounded in our study data 
because the mean age in the unvaccinated group is significantly higher than 
that in the breakthrough group (8.82 y vs 7.72 y). To alleviate this selection 
bias, however, we employed age as a confounder in the logistic model. 
There could be also recall bias because the reporter would fill out the 
epidemiological survey depending on his or her memory. In addtion, in the 
epidemiological survey form, the questionnaire about the number of lesions 
only request the range of the number with a broad bracket(<50, 50-249,
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250-499, ≥500) rather than a concrete number of lesions, which makes 
unavailable to precisely distinguish disease severity from another. Case 
definition may affect the findings of this study because the data did not 
distinguish between clinical cases and laboratory-confirmed cases. Unlike 
laboratory-confirmed cases, probable cases are likely to include patients who 
have similar symptoms like rash but are not infected with varicella.
Considering a high vaccine coverage rate, probable cases could be 
categorized into breakthrough group than unvaccinated group. This may have 
resulted in an underestimation of disease severity in breakthrough group. The 
exact impact of a universal one-dose varicella vaccination on disease severity 
could not be assessed due to a lack of previous population-based data on 
varicella vaccination and its effect on severity before adoption of the 
universal vaccination. Furthermore, we could not either estimate changes in 
disease severity over time because there was no data on annual incidence of 
varicella cases categorized by disease severity. Despite these limitations, the 
present study is the first population-based study to assess a universal 
one-dose varicella vaccination on disease severity in Korea and to provide 
an explanation on the recent increase in the incidence rate of varicella after 
introduction of the national varicella vaccination program.
     In conclusion, our study suggest that universal one-dose varicella 
vaccination may have a significant effect on attenuation of disease severity 
in children. Additional prospective study is necessary to assess the






6-1. Increasing varicella incidence rates among children in the Republic of 
Korea: An Age-Period-Cohort analysis
     The study describes the post-licensure epidemiology of varicella 
incidence with an aspect of time and age. There was an increase in the 
incidence rate of varicella between 2006 and 2017 in Korea. During the 
period, the incidence rate also increased for each age strata among children 
aged 0 to 12–year–old with age peak shifted from 4 to 6 years old. Period 
and cohort curves showed similar increasing patterns.
     The result may be explained by primary or/and secondary vaccine 
failure. The former relates to the failed mounting of the immune system to 
produce antibodies initially and the latter relates to the waning of 
vaccine-induced immunity over time. The age peak shifting could be 
associated with secondary failure. The varicella vaccine is merely effective 
in the early years, but, in later, the incidence of breakthrough infection 
jumps as immunity rapidly wanes over time. Historical context that high 
vaccination coverage prior to the introduction of varicella vaccine into 
national immunization program in Korea may affect the result. 
6-2. Spatial epidemic characteristics and risk factor analysis of varicella 
in the Republic of Korea
     The second study describes the post-licensure epidemiology of varicella 
incidence with an aspect of time and space. During the surveillance periods 
of 2006–2017, local spatial clusters with high level of varicella incidence 
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were initially confined to northeast region (Gangwon-do), rural and mountain 
area. In later, the ‘hot spots’ gradually spread to their neighboring districts 
and faded out over time, which led overall increase in varicella incidence 
across the country. In spatial regression analysis, childhood percentage was
risk factors on the incidence of varicella at district level while factors such 
as population density and number of hospitals have negative effect on the 
risk. Meanwhile, vaccination coverage rate resulted to have nothing to do 
with varicella incidence.
     This may indicate that a district where has a low population density 
and a few healthcare providers and more childhood percentage was
vulnerable to varicella outbreak.
6-3. Effectiveness of varicella vaccination program in preventing 
laboratory-confirmed cases in children in Seoul, the Republic of Korea
     The third study was to evaluate the effectiveness of one-dose varicella 
vaccination program in Korea by performing a matched case-control on 
children in Seoul to investigate if there is primary or/and secondary vaccine 
failure. The result showed that the overall effectiveness of one-dose varicella 
vaccination in preventing confirmed cases of varicella was low (13%, 95% 
CI: -17.3–35.6) and the vaccine effectiveness sharply declined after the three 
year of vaccination due to waning of immunity. In specific, The fact that 
more than half of all vaccinees were immunized with the vaccine based on 
MAV strain and only available in Korea was distinct from the cases in 
other countries where adopted routine varicella vaccination and experienced 
70
substantial decrease in incidence of varicella. 
     This finding may provide a key to understand the increasing trend of 
varicella incidence following implementation of universal vaccination program 
in Korea. Due to an insufficient immunogenicity of the vaccine might have 
limited effectiveness to decrease in the incidence of varicella.
6-4. Effects of one-dose varicella vaccination on disease severity in children 
in Seoul, the Republic of Korea
     The last study also assessed vaccine effectiveness with an aspect of 
effects on disease severity. The result suggested that one-dose vaccination 
was associated with the attenuation of disease severity in children varicella 
cases despite the vaccination failed to protect against varicella incidence. The 
risk for severe illness was significantly decreased in breakthrough group 
(vaccinated group) than unvaccinated group (14.6% vs. 25.8%; OR=0.570).
     This implicates that a universal one-dose varicella vaccination program 
may have limited effectiveness to decrease in the incidence rate of varicella 
but have positive effect in attenuation of disease severity in children 
varicella cases. In addition, patients whose mild symptoms can also transmit 
varicella to others and often cause failure to isolation, leading to outbreaks 
among those with close contacts in education facilities. Therefore, a recent 
increase in the incidence rate of varicella in Korea may be associated with 
a growing number of breakthrough cases.
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6-5. Implications for varicella vaccination policy and future researches
     It has been more than a decade since the implementation of universal 
one-dose varicella vaccination. Nevertheless, incidence of varicella has been 
continuously rising and spatially spreading out across the country. 
Meanwhile, the overall effectiveness of vaccine and vaccination policy have 
not been properly examined. 
     In conclusion, an increase in incidence of varicella was attributed to 
vaccine failure. Insufficient immunogenicity of the vaccine for a low vaccine 
effectiveness and a rapid waning of immunity have failed to prevent from 
incidence of varicella. The vaccine’s positive effect in attenuation of disease 
severity also might cause a growing number of breakthrough cases as being 
unsuccessful in isolating patients with mild symptoms.
     In this regard, to prevent and control of varicella incidence and to 
reduce the disease burden in Korea, enhancing the effectiveness of the 
vaccine is important. Moreover, varicella vaccine is a live attenuated vaccine 
so that distribution and storage of vaccine, so called ‘cold-chain system’, 
should be carefully managed by healthcare providers. Unless the vaccine 
failure be overcome, introducing of a routine two-dose vaccination is merely 
a secondary issue. 
     Further researches should be conducted on herpes zoster along with 
varicella because they are both infectious disease caused by the same VZV 
virus and exogenous boosting by VZV exposure may play a role in HZ 
incidence by maintain cell-mediated immunity. Developing a mathematical 
model to predict incidence of both varicella and HZ by comparing multiple 
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vaccination strategies is consider to be a meaningful work in establishing an 
evidence-based vaccination policy.
     Varicella is a preventable disease when administerd vaccine works 
properly. Through continuous monitoring and evaluation of vaccination 
policies against varicella using national surveillance system, we could 
develop more effective approaches for more effective control and prevention 
of varicella transmission in the Republic of Korea.
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수두는 전염력이 매우 높은 급성 감염 질환으로 수두-대상포진바이러스가 
원인이며, 영유아에 흔한 질병이다. 수두역학은 수두백신 도입 이후 극적
으로 변화하였으며, 수두백신은 세계적으로 질병발생과 질병부담을 감소시
키는데 아주 효과적이다. 그러나 한국에서는 2005년부터 수두백신 1회 국가
예방접종을 실시했음에도 불구하고 2006년부터 2017년 동안 수두발생이 
계속 증가하고 있다. 이 연구는 한국에서 수두백신 도입 이후 수두역학의 
변화를 살펴보고 백신효과를 평가하는 것을 목적으로 한다. 세부적으로는,
(1) 연령, 기간, 코호트 효과가 시간에 따른 국내 영유아 수두발생 증가에 
어떠한 영향을 미쳤는지 연령-기간-코호트 분석을 통해 알아본다.
(2) 수두발생의 공간적 패턴과 지리적 위험요인을 공간분석과 공간회귀모형
적합을 통해 알아본다.
(3) 수두백신 1회 국가예방접종이 수두발생에 미친 효과를 환자-대조군 연구
를 통해 평가한다.
(4) 수두백신이 감염 시 질병 중증도에 미치는 영향을 평가한다. 
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연구 방법
(1) 국가감염병감시시스템에서 수집된 2006년 1월부터 2017년 12월까지 
신고 된 수두발생 자료와 통계청 인구자료를 활용하였다. 연령, 기간, 
코호트 효과를 평가하기 위해 연령-기간-코호트 분석을 사용하였으며,
분석은 Rosenberg가 개발한 APC Web Tool을 통해 실시하였다. 
(2) 국가감염병감시시스템에서 수집된 2006년 1월부터 2017년 12월까지 신고
된 250개 시군구 수두발생 자료와 사회인구학적자료는 통계청 자료를 
활용하였다. 전체 및 부분공간자기상관은 Moran’s I 및 LISA를 통해 
측정하였다. 수두발생의 사회인구학적 요인을 탐지하기 위해 시군구 수준
에서 공간회귀분석을 실시하였으며, spatial error 모형을 이용하였다.
(3) 국가감염병감시시스템에 환자로 신고 된 537명 수두환자와 개별매칭
된 537명 대조군 자료를 이용하였다. 수두환자는 2013년 1월부터
2013년 12월까지 서울특별시에서 발생한 확진환자이다. 수두백신 1회
접종의 효과를 평가하기 위해 1:1 매칭 짝(pair)에 대하여 conditional 
logistic 회귀분석을 실시하였으며, 성별 백신접종연령과 같은 잠재적 
교란변수를 포함시켜 보정하였다. 백신접종이후 시간에 따른 효과를 
측정하기 위해 이를 가변수로 코딩하여 모형에 포함시켰다.  
(4) 질병관리본부가 제공하는 수두환자 역학조사 자료를 이용하였으며, 연구
대상은 2015년 1월부터 2017년 12월까지 역학조사를 통해 보고된 서울
시 거주 1,125명의 수두환자이다. 질병 중증도는 수포개수로 분류하여 
정의하였다. 수두접종 및 미접종 집단에 대하여 중증도를 알아보기 위해
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unconditional logistic 회귀분석을 실시하였으며, 모형에서 연령을 
보정하였다.
결과
(1) 2006년부터 2017년까지 수두환자 발생 수와 연령표준화된 발생률은 우
상향하는 경향성을 보였다. 수두발생률은 0-12세 영유아의 모든 연령
대에서 증가하였고, 다발연령(age peak)은 4세에서 6세로 이동하였다. 
APC분석에서 기간 및 코호트 그래프는 모두 유사한 증가양상을 보였다.
(2) 수두발생수가 높은 지역적 공간군집은 초기에 농어촌 산악지역인 북동부
지역(강원도)에만 국한되어 나타났다. 시간이 지남에 따라 ‘핫스팟’은 
인근지역으로 점차 확산되어 사라졌으며, 전국적으로 전체 수두발생수
가 증가되는 결과를 초래하였다. 공간회귀분석 결과 인구밀도와 의료
기관 수는 수두발생에 음(-)의 효과를 영유아수의 비율은 양(+)의 효과
를 갖는 것으로 나타났으며, 백신접종률은 유의하지 않았다.
(3) 짝짓기된(matched) 환자-대조군 연구에서 확진환자 예방과 관련된 수두
백신 1회접종의 백신효과는 낮은 수준이었으며 (13%, 95% CI: -17.3
–35.6), 백신효과는 접종 3년 이후 부터 면역감소로 인해 급격하게 감소
하였다.
(4) 서울시 거주 1,008명의 환자 중 869명(86.2%)은 돌파감염자이고 139명
(13.8%)은 백신미접종자였다. 중증도 위험은 돌파감염군(백신접종군)에
서 백신미접종군보다 유의하게 감소하였다. 돌파감염군에서 중증도가 
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moderate-to-severe하게 발생할 위험은 백신미접종군보다 약 절반가량
낮게(OR = 0.570, CI: 0.365–0.890) 나타났다.
결론
(1) 첫 번째 연구는 수두백신 도입 이후 시간과 발생 연령 측면에서의 수두
역학을 기술하고 있다. 수두발생의 증가 양상은 백신실패로 설명할 수 
있을 것이다. 다발연령 상승은 시간이 지남에 따라 면역이 감소되는 백신
의 2차실패와 연관이 있는 것으로 보인다. 수두백신은 접종 초기에만 
예방효과가 있을 뿐 이후에는 백신에 의한 면역력이 급감함에 따라 돌파
감염수가 급증하게 된다.
(2) 두 번째 연구는 수두백신 도입 이후 시간과 공간 측면에서의 수두역학을
기술하고 있다. 연구결과에 따르면 우리나라의 전반적 수두발생 증가는 
수두발생률이 높은 클러스터로부터 주변지역으로의 확산에 따른 것으
로도 볼 수 있다. 인구밀도가 낮으며 의료기관 수가 적은 가운데 수두 
위험군인 영유아의 수가 많은 경우 수두 유행에 취약한 것으로 나타났다. 
(3) 세 번째 연구는 한국의 수두백신 1회 접종 정책의 효과를 평가하고 있
다. 백신효과가 낮고 접종 이후 면역이 급감하는 것으로 볼 때 1, 2차 
백신실패가 존재함을 알 수 있다. 이는 백신정책 도입 이후에도 수두발생
이 증가하고 있는 현상을 이해하는 데 핵심이 된다. 백신에 의한 면역력
이 충분하지 못함에 따라 수두발생을 감소시키는 데 있어 수두백신 효과
가 제한됨을 알 수 있다.
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(4) 네 번째 연구는 수두백신이 질병 중증도에 미치는 효과를 평가하고 있다. 
연구 결과 수두백신 1회접종은 영유아의 수두 중증도를 완화시키는 것
으로 나타났다. 다만 증상이 미약한 환자는 타인에게 수두를 전파시킬 
수 있음에도 격리가 제대로 되지 않아 보육시설의 근접 접촉자들에게 
수두 유행을 야기할 수 있다. 따라서 최근 한국의 수두발생률의 증가는 
이에 따른 돌파감염의 증가와 연관이 있는 것으로 볼 수 있다. 
